home about us home home
facebook facebook facebook
It is a pleasure to announce that next WorldLeish 6 congress will be organized by the Instituto de Salud Carlos III (ISCIII, Spain) and the Drugs for Neglected Diseases initiative (DNDi, Switzerland) in Toledo - a world heritage city. By the end of January the will be active with preliminary information and more to follow soon after.
From: 16th to 20th May 2017 Heritage City
Website : www.WL6.org
June 28th-July 1st, 2016 Reims, France
Website : ISOPS 9 - 2nd circular
World Federation of Parasitologists
Newsletter Report

10thDecember, 2015
WFP - founded in Warsaw, Poland, 1960
June 28th-July 1st, 2016 Reims, France
Website : www.isops9.org
Dr Neeloo Singh has been awarded
Prof. B.K. Aikat Oration Award 2012
by Indian Council of Medical Research
This award is in recognition for her work on whole genome sequencing of clinical isolates of Leishmania in India
Barcelona Institute for Global Health is recruiting 15 PhD Fellows! to Control Leishmaniasis: biologists, epidemiologists, veterinarians, physicians, parasitologists, IT engineers, economists, etc
Marianne Comparet
Director at The International Society for Neglected Tropical Diseas
A vaccine for Kala-azar within reach?
The Hindu, September 12, 2013
Neeloo Singh team member of an Indo-Sri Lankan delegation for a workshop on "Update on clinical, diagnostic, chemotherapeutic and vector aspects of Leishmaniasis" in Colombo, Sri Lanka, 25-28 March 2013. Supported by Department of Science & Technology, Government of India and Ministry of Technology Research, Government of Sri Lanka.
Neeloo Singh delivered Prof. A.N. Bhaduri Memorial Lecture 4th May 2012 at B.C. Guha Centre, Baylliganj Science College, Kolkata.

September, 2018

  • S
  • M
  • T
  • W
  • Th
  • F
  • Sa
  • 01
  • 02
  • 03
  • 04
  • 05
  • 06
  • 07
  • 08
  • 09
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
Locations of visitors to this page

Latest Activities
The birth of the first Indian Leishmania Genome Sequence
Prelude to whole genome sequencing of Leishmania donovani clinical isolates.

 Oscar Kala Azar Rapid Test
A rapid immunochromatographic assay for the qualitative detection of antibodies (against rK39) to visceral leishmaniasis (VL). N: Healthy Control, pA; pB; pC; pD: Kala Azar (VL) patients.
  In 1903, W.B. Leishman and C. Donovan reported this new parasite at the turn of the century. Ronald Ross christened the new genus Leishmania and the new species donovani in year 1903.

The history of kala azar in India is one of the great stories of tropical medicine. The invaluable account of this disease from the time great epidemics swept across vast tracks of the Indian subcontinent leaving misery and poverty in their wake up to the present time is foretold in the publication launched during WorldLeish4, Kala Azar: An Odyssey into the Past,  ISBN 81-8189-281-X.

Visceral Leishmaniasis (VL): The Indian subcontinent (India, Nepal & Bangladesh) is one of the main areas affected by VL worldwide. It accounts for about 67% of total cases reported with almost 200 million people at risk of contracting the disease. The governments of India, Bangladesh and Nepal have launched a joint programme to eliminate VL as a public health problem by the year 2012.


We now embark on a project to unravel the genome of this causative agent and explore ways and means to reduce the risk of this disease to the population in peril and to improve the treatment of patients.


No effective vaccine is yet available against this parasite & its control relies primarily on chemotherapy. Since the discovery of the pentavalent antimonials, (the first drug for leishmaniasis treatment, IJMR 1922,10:492), until today, the search for lead molecules with antileishmanial activity, without toxic effects, & able to overcome the emergence of drug resistant strains, still remains as the current goal. We have carried out microarray monitoring of gene expression in drug unresponsive clinical isolates collected from the disease endemic region of Bihar. These  initial studies dealt with limited number of genes and now genome wide survey will yield an enhanced perspective. The objective of the proposed study is to carry out  whole genome sequencing of Leishmania donovani clinical isolates using next generation sequencing technology, to compare them at genome level. The analysis of the whole genome can provide useful information about the complex events leading to resistance.

The study  is jointly sponsored by Leishmaniasis  Research Society (India) at  Central Drug Research Institute, Lucknow and Department of Biotechnology, India.